Related Experiment Video
Updated: Jul 16, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026
Abstract:
The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, exerts critical regulatory roles in cellular processes including proliferation, migration, invasion, and angiogenesis. As a key driver gene in non-small cell lung cancer (NSCLC), MET abnormalities encompass MET exon 14 (METex14) skipping mutations, gene amplification, protein overexpression, gene fusions, and activating mutations. This consensus, developed by the Lung Cancer Specialty Committee of the Chinese Elderly Health Care Association, updates the 2025 version with several key modifications: elevating the recommendation level for MET amplification and protein overexpression testing, advocating routine testing for all newly diagnosed NSCLC patients and those with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); standardizing targeted therapy approaches for MET amplification in driver gene-negative settings and following EGFR-TKIs resistance; and subdividing MET protein overexpression-related management into post-EGFR-TKIs resistance and driver gene-negative categories with corresponding treatment protocols, thereby offering more actionable guidance for precise clinical decision-making. .
Insights
This consensus updates guidelines for MET gene testing and targeted therapies in non-small cell lung cancer (NSCLC). It emphasizes routine MET testing and refines treatment strategies for MET amplification and overexpression, especially after resistance to EGFR-TKIs.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The MET gene plays a crucial role in non-small cell lung cancer (NSCLC) development and progression.
- MET abnormalities, including MET exon 14 skipping, amplification, and overexpression, are key drivers in NSCLC.
- Current management strategies require updates to incorporate recent advancements in testing and targeted therapies.
Purpose of the Study:
- To provide updated consensus guidelines for the Chinese Elderly Health Care Association regarding MET gene abnormalities in NSCLC.
- To refine recommendations for MET testing and targeted therapy selection in newly diagnosed and treatment-resistant NSCLC patients.
- To offer enhanced clinical decision-making guidance for managing MET-driven NSCLC.
Main Methods:
- Development of consensus recommendations by the Lung Cancer Specialty Committee.
- Review and integration of the latest research on MET alterations and their clinical implications.
- Modification of existing guidelines based on new evidence and clinical experience.
Main Results:
- Elevated recommendation levels for MET amplification and protein overexpression testing in NSCLC.
- Advocacy for routine MET testing in all newly diagnosed NSCLC and EGFR-TKI-resistant cases.
- Standardized targeted therapy approaches for MET amplification and subdivided management for MET protein overexpression.
Conclusions:
- Updated guidelines provide actionable strategies for precise clinical decision-making in MET-driven NSCLC.
- Routine MET testing and tailored therapies are crucial for improving patient outcomes.
- The consensus addresses critical aspects of MET-targeted treatment, including resistance mechanisms and specific patient populations.